Recombinant coagulation factor VII is a very important and complex protein employed for treatment of hemophiliac patients (hemophilia A/B) who develop inhibitors antibodies to conventional treatments (FVIII and FIX). The rFVII is a glycosylated molecule and circulates in plasma as zymogen of 50 kDa. When activated the molecule is cleaved to 20–30 kDa and has a half-life of about 3 h, needing to be processed fast and efficiently until freeze-drying. Here, we describe a very simple and fast purification sequence for rFVII using affinity FVII Select resin and a dialysis system that can be easily scaled up.
CITATION STYLE
Granovski, V., Freitas, M. C. C., Abreu-Neto, M. S., & Covas, D. T. (2018). Purification and autoactivation method for recombinant coagulation factor VII. In Methods in Molecular Biology (Vol. 1674, pp. 221–226). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7312-5_18
Mendeley helps you to discover research relevant for your work.